Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma
<p>Abstract</p> <p>Background</p> <p>Xenobiotic Metabolizing Enzymes (XMEs) contribute to the detoxification of numerous cancer therapy-induced products. This study investigated the susceptibility and prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-04-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/8/109 |
id |
doaj-0c35143c881a4e338a150ef5272ce7d0 |
---|---|
record_format |
Article |
spelling |
doaj-0c35143c881a4e338a150ef5272ce7d02020-11-25T00:05:19ZengBMCBMC Cancer1471-24072008-04-018110910.1186/1471-2407-8-109Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast CarcinomaGabbouj SallouhaBouaouina NoureddineHassen ElhamKhedhaier AchrafAhmed SlimChouchane Lotfi<p>Abstract</p> <p>Background</p> <p>Xenobiotic Metabolizing Enzymes (XMEs) contribute to the detoxification of numerous cancer therapy-induced products. This study investigated the susceptibility and prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene polymorphisms in breast carcinoma patients.</p> <p>Methods</p> <p>The authors used polymerase chain reaction and restriction enzyme digestion to characterize the variation of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene in a total of 560 unrelated subjects (246 controls and 314 patients).</p> <p>Results</p> <p>The mEH (C/C) mutant and the NAT2 slow acetylator genotypes were significantly associated with breast carcinoma risk (p = 0.02; p = 0.01, respectively). For NAT2 the association was more pronounced among postmenopausal patients (p = 0.006). A significant association was found between CYP2D6 (G/G) wild type and breast carcinoma risk only in postmenopausal patients (p = 0.04). Association studies of genetic markers with the rates of breast carcinoma specific overall survival (OVS) and the disease-free survival (DFS) revealed among all breast carcinoma patients no association to DFS but significant differences in OVS only with the mEH gene polymorphisms (p = 0.02). In addition, the mEH wild genotype showed a significant association with decreased OVS in patients with axillary lymph node-negative patients (p = 0.03) and with decreasesd DFS in patients with axillary lymph node-positive patients (p = 0.001). However, the NAT2 intermediate acetylator genotype was associated with decreased DFS in axillary lymph node-negative patients.</p> <p>Conclusion</p> <p>The present study may prove that polymorphisms of some XME genes may predict the onset of breast carcinoma as well as survival after treatment.</p> http://www.biomedcentral.com/1471-2407/8/109 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gabbouj Sallouha Bouaouina Noureddine Hassen Elham Khedhaier Achraf Ahmed Slim Chouchane Lotfi |
spellingShingle |
Gabbouj Sallouha Bouaouina Noureddine Hassen Elham Khedhaier Achraf Ahmed Slim Chouchane Lotfi Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma BMC Cancer |
author_facet |
Gabbouj Sallouha Bouaouina Noureddine Hassen Elham Khedhaier Achraf Ahmed Slim Chouchane Lotfi |
author_sort |
Gabbouj Sallouha |
title |
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_short |
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_full |
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_fullStr |
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_full_unstemmed |
Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma |
title_sort |
implication of xenobiotic metabolizing enzyme gene (cyp2e1, cyp2c19, cyp2d6, meh and nat2) polymorphisms in breast carcinoma |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2008-04-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Xenobiotic Metabolizing Enzymes (XMEs) contribute to the detoxification of numerous cancer therapy-induced products. This study investigated the susceptibility and prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene polymorphisms in breast carcinoma patients.</p> <p>Methods</p> <p>The authors used polymerase chain reaction and restriction enzyme digestion to characterize the variation of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene in a total of 560 unrelated subjects (246 controls and 314 patients).</p> <p>Results</p> <p>The mEH (C/C) mutant and the NAT2 slow acetylator genotypes were significantly associated with breast carcinoma risk (p = 0.02; p = 0.01, respectively). For NAT2 the association was more pronounced among postmenopausal patients (p = 0.006). A significant association was found between CYP2D6 (G/G) wild type and breast carcinoma risk only in postmenopausal patients (p = 0.04). Association studies of genetic markers with the rates of breast carcinoma specific overall survival (OVS) and the disease-free survival (DFS) revealed among all breast carcinoma patients no association to DFS but significant differences in OVS only with the mEH gene polymorphisms (p = 0.02). In addition, the mEH wild genotype showed a significant association with decreased OVS in patients with axillary lymph node-negative patients (p = 0.03) and with decreasesd DFS in patients with axillary lymph node-positive patients (p = 0.001). However, the NAT2 intermediate acetylator genotype was associated with decreased DFS in axillary lymph node-negative patients.</p> <p>Conclusion</p> <p>The present study may prove that polymorphisms of some XME genes may predict the onset of breast carcinoma as well as survival after treatment.</p> |
url |
http://www.biomedcentral.com/1471-2407/8/109 |
work_keys_str_mv |
AT gabboujsallouha implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT bouaouinanoureddine implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT hassenelham implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT khedhaierachraf implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT ahmedslim implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma AT chouchanelotfi implicationofxenobioticmetabolizingenzymegenecyp2e1cyp2c19cyp2d6mehandnat2polymorphismsinbreastcarcinoma |
_version_ |
1725425798432686080 |